- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: The objective of this study is Korean mistletoe lectin (Viscum album coloratum agglutinin, VCA) and bee venom (BV) to experimental prove comparative study of VCA and BV on the anti-cancer effect and mechanisms of action. Methods: In this study, it was examined in a human hepatocellular carcinoma cell line, Hep G2 cells. Cytotoxic effects of VCA and BV on Hep G2 cells were determined by 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT) assay in vitro. VCA and BV killed Hep G2 cells in a time- and dose-dependent manner. Results: The apoptotic cell death was then confirmed by propidium iodide staining and DNA fragmentation analysis. The mechanisms of action was examined by the expression of anti-apoptotic proteins and activation of mitogen-activated protein kinases. Treatment of Hep G2 cells with VCA activated poly (ADP-ribose) polymerase-1 (PARP-1) known as a marker of apoptosis, and mitogen-activated protein kinases signaling pathways including SAPK/JNK, MAPK and p38. BV also activated PARP-1, MAPK, p38 but not JNK. The expression level of anti-apoptotic molecule, Bcl-X, was decreased by VCA treatment but not BV. Finally, the phosphorylation level of ERM proteins involved in the cytoskeleton homeostasis was decreased by both stimuli. Conclusion: We examined the involvement of kinase in VCA or BV - induced apoptosis by using kinase inhibitors. VCA-induced apoptosis was partially inhibited by in the presence
1. Ahn YO, Park BJ, Yoo KY, Lee HS, Kim CY, Shigematsu T. Incidence estimation of primary liver cancer among Koreans. Journal of Korean Cancer Association. 1989:241-248.
2. The Ministry of Health and Welfare. the Korea Central Cancer Registration Center, and the annual report of Korea's Central Cancer Registration Project. 2015
3. Stein GM, Schetzel M, Bussing A. Mistletoe in immunology and the clinic(short review). Anticancer Research. 1998;18:3247-9.
4. Stein GM, Pfuller U, Schietzel M. Viscotoxin-free aqueous exyracts from European mistletoe (Viscum album L.) stimulate activity of human granulocytes. Anticancer Research. 1999;19:2925-8.
5. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing and anticancer effects of bee venom and its constituent compounds, Pharmacol Ther. 2007 Aug;115(2):246-70.
6. Xia, Z., Dickens, M., Raaingeaud, J., Davis, R. J. and Rincon, M. E. : Opposing effects of ERK and JNK-p38 MAPkinases on apoptosis. Science 270, pp.1326-1331, 1995.
7. Karasavvas, N. and Zakeri, Z. Relationships of apoptotic signaling mediated by ceramide and TNF-alpha in U937 cells. Cell Death Differ. 1999;6:115-123.
8. Kawasaki H, Morooka T, Shimohama S, Kimura J, Hirano T, Gotoh Y. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 1997;272:18518-18521.
9. Kondo T, Takeuchi K, Doi Y, Yonemura S, Nagata S, Tsukita S. ERM (ezrin/radixin/moesin)-based molecular mechanism of microvillar breakdown at an early stage of apoptosis. J Cell Biol. 1997;139(3):749-58.
10. Bussing A. Suzart K, Bergmann L, Pfuller U, Schietzel M, Schweizer K. Induction of apoptosis in human lymphocytes treated with Viscum album L is mediated by the mistletoe lectins. Cancer Lett. 1996;99:59-72.
11. Park RK, Kim MS, So HS, Jung BH, Moon SR, Chung SY, et al. Activation of c-Jun N-termonal Kinase 1(JNK1) in Mistletoe Lectin Ⅱ-induced Apoptosis of Human Myeloleukemic U937 Cells. Biochemical Pharmacology. 2000;60:1685-1691.
12. Stoss M, Peter E, Gorter RW. Decrease of activated lymphocytes four and nine hours after a subcutaneous injection of a Viscum album L. extract in healthy volunteers. Nat Immun. 1998;16(5-6):185-97.
13. Fischer S, Scheffler A. Kabelitz. Oligoclonal in vitro Response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Biomed Pharmacother. 2000;54(6):305-10.
14. Park WB, Kim HS, Na HB, Ham SS. Changes in the lethin content, pH, temperature effects, and sugar-specific lymphocytic stimulation effects during mistletoe fermentation. Journal of Pharmaceutical Affairs. 1995;39(1:24-30)
15. Tasneem A, Khwaja O, Cecilia B, Stephanie P. Recent studies on the Anticancer Activities of Mistletoe(Viscum album) and Its alkaloids. Oncology. 1986;43(1):42-50.
16. Moon DO, Park SY, Choi YH, Kim ND, Lee C, Kim GY. Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells, Toxicon. 2007 Sep 2;Epub ahead of print.
17. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–6.
18. Chiarugi A. (2002) Poly(ADP-ribose) polymerase:killer or conspirator? The ‘'suicide hypothesis’'revisited. Trends Pharmacol. Sci. 23:122–129.
19. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature. 1994 Sep 22;371(6495):346-7.
20. Chiarugi A. (2002) Poly(ADP-ribose) polymerase:killer or conspirator? The ‘'suicide hypothesis’'revisited. Trends Pharmacol. Sci. 23:122-129
21. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993 Aug 27;74(4):597-608.
22. Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta. 2008 Nov;1780(11):1325-36. Epub 2008 Jan 16. Review
23. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways, Cell. Mol. Life Sci. 1999;55:1230–1254.
24. Borsello T, Clarke PG, Hirt A, Vercelli M, Repici DF, Schorderet J, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia, Nat. Med. 2003;9:1180–1186.
25. Shiue H, Musch MW, Wang Y, Chang EB, Turner JR. Akt2 phosphorylates ezrin to trigger NHE3translocation and activation. J Biol Chem. 2005;280(2):1688-1695.
26. Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res. 2004 Jan;27(1):68-76.